The FDA’s approval of a nasal mist flu vaccine for at-home use represents more than just a convenient alternative to the traditional flu shot — it marks a significant shift in healthcare delivery, moving toward a decentralized model where patients can self-administer care from the comfort of their own homes.
The FDA’s approval of a nasal mist flu vaccine for at-home use represents more than just a convenient alternative to the traditional flu shot — it marks a significant shift in healthcare delivery, moving toward a decentralized model where patients can self-administer care from the comfort of their own homes.
Lirio’s Behavioral Reinforcement Learning Lab (BReLL) recently published a paper describing a new approach, the Limited Data Estimator, for comparing reinforcement learning policies using limited historical data.